Founded in 2010 Myelomax is a spin-off of the Multiple Myeloma Nantes Academic Group established by INSERM (the French National Research Institute) and the University of Nantes. Emmanuelle Ménoret PhD heads up the preclinical research organization which includes leading cancer researchers and specialists on its scientific advisory board. Myelomax continues to work alongside researchers and clinicians at a world-renowned myeloma cancer center. And importantly is currently working to bring more proprietary cell lines to market so expanding its unique collection and understanding of this highly heterogeneous and still incurable disease.
Myelomax is the only preclinical CRO wholly dedicated to Multiple Myeloma worldwide and has accumulated over 5 years dedicated experience in Multiple Myeloma preclinical research with over 1600 assay tests to date against 34 molecules. Our database includes results of assays conducted on today’s current standard of care agents in 38 cell lines that are representative of heterogeneity of this cancer.
We are experts in human myeloma cell line testing and evaluation both in-vitro and in vivo. Unlike other generalist or non-specialist preclinical CROs, this means we are well placed to provide unique advice on which cell lines are the most appropriate for your study.